Acadia Pharmaceuticals
ACAD
256 hedge funds and large institutions have $2.4B invested in Acadia Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 90 increasing their positions, 80 reducing their positions, and 42 closing their positions.
151% more call options, than puts
Call options by funds: $16M | Put options by funds: $6.39M
13% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 80
3% less funds holding
Funds holding: 264 → 256 (-8)
3.3% less ownership
Funds ownership: 97.52% → 94.22% (-3.3%)
8% less capital invested
Capital invested by funds: $2.62B → $2.4B (-$214M)
17% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 42
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$20.3M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$15.4M |
| 3 |
O
OrbiMed
New York
|
+$12.8M |
| 4 |
Two Sigma Investments
New York
|
+$12.7M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$60.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$26.5M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.9M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$15.1M |
ACAD Hedge Fund Activity: Q3 2024 in Review
256 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2024, worth a combined $2.4B — down 8.2% from $2.62B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ACAD and 35 opened new positions — a net loss of 7 holders — while 80 trimmed existing stakes and 90 added.
The largest buyer was Man Group, adding an estimated $20.3M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $60.3M sold.
- 256 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2024, down from 264 in Q2 2024.
- Funds reported $2.4B of Acadia Pharmaceuticals stock for Q3 2024, down 8.2% quarter-over-quarter.
- 35 funds opened new Acadia Pharmaceuticals positions in Q3 2024 and 42 closed out, a net change of -7 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2024 was Man Group, an estimated $20.3M added.
- The largest Acadia Pharmaceuticals seller in Q3 2024 was Point72 Asset Management, an estimated $60.3M sold.
Based on aggregated 13F filings for Q3 2024.